Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

<i>MTHFR</i>677C → T genotype modulates the effect of a 5-year supplementation with B-vitamins on homocysteine concentration: The SU.FOL.OM3 randomized controlled trial by Leopold K. Fezeu (5309333)

“…</p><p>Methods</p><p>2381 patients with a personal history of cardiovascular disease were randomly assigned to one of four groups: 1) B-vitamins alone (560 μg of 5-methyl-THF, 3 mg of vitamin B₆ and 20 μg of vitamin B₁₂), 2) n-3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio), 3) B-vitamins and n-3 fatty acids, and 4) placebo. …”

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Accumulated immature APP in response to IDN5706 is degraded by Atg5-dependent autophagy. by Viviana A. Cavieres (500139)

Effect of atipamezole or efaroxan (0.5 mg·kg⁻¹) (Protocol 2). by Yoichiro Kitajima (4319455)

Subjects:

Inhibition of MMP2 decreases apoptosis and attenuates insulin secretion dysfunction caused by oxidative stress in INS-1 cells. by Chongxiao Liu (644813)

In vitro CA4P toxicity assay. by Anja Bille Bohn (641992)

Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. by Régis Cohen (11419436)

Subjects:

Three Ca_V3.3 variants left-shift the window current, while the A398V completely abolishes the window current. by Yousra El Ghaleb (22075892)

Subjects:

Fig 5 - by Fatemeh Mohammadkhani (15927311)

Mean and standard deviation values of <i>p</i> and <i>q</i> distributions shown in Fig 5, and generated with a rolling, overlapping time window of 252 days. by Héctor Raúl Olivares-Sánchez (13014866)

Effects of FE and RUD wrist postures on the mean shape signature phase shift within each quartile. by Drew A. Anderson (14197446)

Subjects:

Unaltered energy expenditure and decreased physical activity in chow-fed mice with adult-onset hypothalamus-specific Y1Y5 receptor deletion. by Amy D. Nguyen (153830)